shouyebanner1-454.jpg banner-shoujishouye1.jpg

Let Cell Therapies Eradicate Cancer Cells

See More

shouyebanner2-287.jpg banner-shoujishouye2.jpg

Neukio Biotherapeutics on a New Mission

shouyebanner3-907.jpg banner-shoujishouye3.jpg

Quality-based
Specification-oriented
Patient-centered
Building new future in cell therapy

About Neukio

Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.


Allogenic

Scalability

Solid tumors

indications

Why iPSC-CAR-NK?

1. NK cells can be universal and readily available (allogeneic use)

2. NK cells can be manufactured in scale via iPSC differentiation and banking

3. Engineered NK have potential to eradicate solid tumors

syerxuz-195.svg

Gene Editing

NK Diff. & Exp.

DP

Banking

iPSC Bank

shoujiduannksucai.png

About Founder

Richard Liqun Wang Ph. D., MBA.

Founder, Chairman and CEO, Neukio Biotherapeutics


Former positions held: 

-   VP & CTO, Fosun Pharma

-   Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years

-   COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies

-   Head of Operations, GSK R&D Center in China

-   Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China

-   Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA

-   Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA



undefined